VolitionRx Announces Breakthrough Clinical Data for Nu.Q® Vet Cancer Test in Cats

Rhea-AI Summary

Volition (NYSE AMERICAN: VNRX) reported clinical study results for the Nu.Q® Vet Feline assay showing 100% specificity and detection of over 80% of feline lymphomas, supporting development of a blood-based liquid biopsy for cats. The company cites a U.S. population of 73.8 million pet cats, ~1-in-5 cats estimated to develop cancer, >18 million senior cats (8+), and a North American veterinary oncology market projected at $1.77 billion by 2025. Management expects a peer-reviewed publication, a $5 million contractual milestone, and commercial rollout via existing lab and point-of-care channels.

Positive

• Assay demonstrated 100% specificity with >80% lymphoma detection
• Potential $5 million contractual milestone tied to publication
• U.S. addressable base of 73.8 million pet cats
• >18 million U.S. senior cats represent recurring screening opportunity
• Nu.Q® Vet Canine already available in 20+ countries, feline test could double TAM
• North American veterinary oncology market projected at $1.77B by 2025

Negative

• None.

Key Figures

Assay specificity 100% specificity Nu.Q® Vet Feline assay detecting feline lymphoma

Detection rate Over 80% of feline lymphomas Detected at 100% specificity in study

U.S. pet cat population 73.8 million cats Addressable companion-animal market in the United States

Cancer lifetime risk 1 in 5 cats Estimated proportion of cats developing cancer

Senior cat segment Over 25% of U.S. cats Cats aged 8+ representing recurring screening opportunity

Screening pool Over 18 million pets Senior U.S. cats eligible for annual screening

Vet oncology market $1.77 billion by 2025 Projected North American veterinary oncology market size

Milestone payment $5 million Contractual milestone expected upon study publication

Market Reality Check

$0.3548 Last Close

Volume Volume 957,549 is below the 20-day average of 2,078,381, suggesting no pre-news volume spike. low

Technical Shares at $0.2857 are trading below the 200-day MA ($0.53) and 69.61% under the 52-week high.

Peers on Argus 1 Up

VNRX was up 3.22% while key diagnostics peers (ICCM, LUNG, TELA, APYX, CTSO) were down between about -0.22% and -5.56%. Momentum scanners only flagged one other stock (WOK) to the upside, indicating today’s strength appears stock-specific rather than sector-driven.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 17	Business review update	Positive	+10.3%	Outlined 2025 commercial and clinical milestones and upcoming feline lymphoma payment.
Dec 11	Technology advance	Positive	+2.6%	Reported Capture-Seq™ method with 180-fold enrichment and strong initial performance.
Dec 08	Clinical data lung cancer	Positive	-0.7%	Presented lung cancer Nu.Q® Cancer biomarker data at a major conference.
Dec 04	Sepsis program inclusion	Positive	+9.5%	Nu.Q® NETs H3.1 chosen as sole biomarker in France’s DETECSEPS program.
Nov 25	First clinical sale	Positive	-10.0%	Announced first Nu.Q® Cancer clinical assay sale for certification in France.

Pattern Detected

Recent news has often produced strong moves, with three notable positive reactions and two sell-the-news pullbacks on otherwise constructive updates.

Recent Company History

Over the last several months, Volition highlighted multiple Nu.Q® milestones. On Nov 25, 2025, it reported the first clinical sale of Nu.Q® Cancer assays in France, followed by France’s DETECSEPS sepsis program inclusion on Dec 4. Subsequent lung cancer data and Capture-Seq™ enrichment results reinforced the platform, and a Dec 17 business review referenced a payable $5 million feline lymphoma milestone. Today’s feline lymphoma data and associated contractual payment fit into this ongoing push to commercialize Nu.Q® across human and veterinary oncology and critical care.

Regulatory & Risk Context

Active S-3 Shelf Registration 2025-07-03

VolitionRx has an effective Form S-3 shelf registration filed on 2025-07-03 and valid until 2028-07-03, with at least 4 recorded 424B usages in 2025. This structure provides flexibility to raise additional capital via registered offerings, which can support ongoing clinical and commercial initiatives but may also introduce future equity dilution for existing shareholders.

Market Pulse Summary

The stock surged +24.2% in the session following this news. A strong positive reaction aligns with the constructive pattern seen around prior Nu.Q® milestones, where several clinical and commercial updates produced double‑digit moves. The feline lymphoma data add high-specificity performance and unlock a $5 million milestone, but historical volatility and the company’s reliance on external financing and an effective S-3 shelf mean any sharp gains could be sensitive to follow‑on capital raises or profit‑taking.

Key Terms

liquid biopsy medical

"world's first simple, affordable blood-based liquid biopsy test for feline cancer"

A liquid biopsy is a laboratory test that looks for tiny pieces of tumor or disease-related material — such as DNA, proteins, or cells — circulating in blood or other body fluids, allowing detection and monitoring without a surgical tissue sample. For investors, it matters because these tests can speed diagnosis, guide treatment choices, enable easier repeat testing, and create recurring revenue streams if adopted widely, affecting a medical company's growth and regulatory risk profile.

lymphoma medical

"accuracy of its Nu.Q® Vet Feline assay in detecting lymphoma in cats"

A cancer that starts in the lymphatic system, the body's network of vessels and nodes that help fight infection and remove waste; it occurs when white blood cells grow out of control and form tumors or spread through that network. For investors, lymphoma matters because its diagnosis, treatment options, drug trial results, and long-term care costs can drive demand for therapies, affect healthcare company revenues, and influence regulatory and reimbursement decisions—similar to how a major product change can reshape a company's market.

compound annual growth rate financial

"expected to grow at a faster Compound Annual Growth Rate than the canine segment"

The compound annual growth rate (CAGR) shows how much an investment or value has grown, on average, each year over a specific period. It considers the effect of growth that compounds or builds upon itself, similar to how interest accumulates in a savings account. Investors use CAGR to compare different investments’ long-term performance and to understand how steady or consistent their growth has been over time.

oncology medical

"The North American veterinary oncology market is projected to reach $1.77 billion"

Oncology is the branch of medicine focused on understanding, diagnosing, and treating cancer, including the development and testing of drugs, therapies, and screening methods. It matters to investors because advances, trial results, regulatory approvals, or setbacks in cancer research can dramatically change the value of companies and the size of potential markets—think of oncology news as weather reports that help investors steer financial decisions in a high-stakes field.

AI-generated analysis. Not financial advice.

Paves the Way for World's First Feline Liquid Biopsy Test for Cancer Detection

HENDERSON, Nev., Jan. 8, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces results from a clinical study demonstrating the high accuracy of its Nu.Q® Vet Feline assay in detecting lymphoma in cats, the most common cancer in the species¹. At 100% specificity, i.e. no false positives, the assay detected over 80% of feline lymphomas² . This breakthrough marks the development of what we expect to be the world's first simple, affordable blood-based liquid biopsy test for feline cancer, a significant unmet need in veterinary medicine. 

Frédéric Wuilque, VP-Global Products, Volition commented :

"Historically, cancer in cats has been notoriously difficult to diagnose early, often requiring invasive biopsies or expensive imaging after symptoms have already progressed. Veterinarians have been asking for a feline solution for years.

"Our mission is to make cancer screening a routine part of every pet's annual wellness check and following the successful international rollout of our canine cancer test, we have now demonstrated that our technology is also effective for cats.

"We look forward to completing product development and making the Nu.Q® Vet Feline Test available through our existing distribution networks including reference laboratories and point-of-care platforms."

The Nu.Q® Vet Feline Test taps into a significant, rapidly growing market:

• Large Population: There are approximately 73.8 million pet cats in the United States alone³.
• High Risk: It is estimated that approximately 1 in 5 cats will develop cancer in their lifetime⁴. Feline lymphoma, the most common cancer in the species, is a primary target for the Nu.Q® assay.
• The "Senior" Segment: Over 25% of U.S. cats are considered seniors (aged 8+)⁵, representing a recurring annual screening opportunity for over 18 million pets in the U.S.^3,5
• Market Growth: The North American veterinary oncology market is projected to reach $1.77 billion by 2025, with the feline segment expected to grow at a faster  Compound Annual Growth Rate than the canine segment due to increasing owner awareness and a growing focus on feline-specific treatments"⁶.

Gael Forterre, Chief Commercial Officer, Volition commented:

"This represents a tremendous commercial opportunity for Volition:

• the publication of this study in a peer reviewed journal is expected subsequently to unlock a $5 million contractual milestone payment.
• we will also generate ongoing revenue,  in this large and growing market where our technology meets an unmet need

"The Nu.Q® Vet Canine test is already available in more than 20 countries, and we believe the addition of a feline equivalent could potentially double our total addressable market in the companion animal space."

1. Vail D, Thamm D, Liptak J, eds. Withrow and MacEwen's Small Animal Clinical Oncology. 6th ed. Elsevier Health Sciences; 2019.
2. Data on file, Volition
3. AVMA Pet Ownership Sourcebook (2025) & APPA National Pet Owners Survey (2025)
4. Can Cats Get Cancer? Understanding Feline Cancers Like Lymphoma & SCC. Imprimed
5. Data on file, Volition TAM model
6. Towards Healthcare: Veterinary Oncology Market Insights (October 2025)

About Volition

About Volition: Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.

Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life.

Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.

The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.

Media Enquiries: Louise Batchelor, Volition, mediarelations@volition.com +44 (0)7557 774620

Investor Relations: Jeremy Feffer, LifeSci Advisors, jfeffer@lifesciadvisors.com +1-212-915-2568

Safe Harbor Statement

Statements in this press release or associated video or link may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, Volition's expectations related to revenue opportunities and growth, the effectiveness and availability of Volition's blood-based diagnostic, prognostic and disease monitoring tests, Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases, Volition's expectations regarding future publications, Volition's success in securing licensing and/or distribution agreements with third parties for its products, and Volition's expectations regarding the terms of such agreements. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.

Nucleosomics™, Capture-PCR™, Capture-Seq™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release or associated video or link are the property of their respective owners. Additionally, unless otherwise specified, all references to "$" refer to the legal currency of the United

View original content:https://www.prnewswire.com/news-releases/volitionrx-announces-breakthrough-clinical-data-for-nuq-vet-cancer-test-in-cats-302656334.html

SOURCE VolitionRx Limited

FAQ

What did Volition announce about the Nu.Q® Vet Feline test on January 8, 2026 (VNRX)?

Volition announced clinical results showing the Nu.Q® Vet Feline assay achieved 100% specificity and detected over 80% of feline lymphomas.

How accurate is the Nu.Q® Vet Feline assay for detecting feline lymphoma (VNRX)?

The study reported 100% specificity (no false positives) and detection of over 80% of feline lymphomas.

When could the Nu.Q® Vet Feline test become commercially available and through which channels (VNRX)?

Management expects to complete product development and offer the test through existing reference laboratories and point-of-care platforms, timing pending final development steps.

What commercial milestone and revenue implications did Volition disclose for the feline test (VNRX)?

A peer-reviewed publication is expected to trigger a $5 million contractual milestone payment and ongoing revenue from testing in a growing market.

How large is the U.S. market opportunity cited for the feline test (VNRX)?

The company cites 73.8 million U.S. pet cats, ~1-in-5 cats developing cancer, and >18 million senior cats as recurring screening opportunities.